Company intelligence / Profile preview

Minoryx Therapeutics

Mataró (Barcelona), Catalonia, Spainminoryx.com ↗

Ownership: Private
Employees: ~34
Development stage: Other

Overview

Minoryx's lead compound leriglitazone (MIN-102) completed a phase 2/3 study in X-ALD (ADVANCE) showing significant reduction of cerebral lesion progression and reduced incidence of cerebral lesions and myelopathy symptoms. A study in pediatric cALD (NEXUS) showed disease arrest or lesion growth stabilization after 24 weeks. A phase 3 study in adult male patients with progressive cALD (CALYX) is currently recruiting in the US with results anticipated by late 2025. The marketing authorization application (MAA) for adult male X-ALD patients is currently under review by the EMA.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

leriglitazone

Partnerships

Neuraxpharm

Beyond the preview

Go deeper on Minoryx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minoryx Therapeutics.